Composite measures of pain, anxiety, and depressive (PAD) symptoms: Construct and predictive validity.


Journal

General hospital psychiatry
ISSN: 1873-7714
Titre abrégé: Gen Hosp Psychiatry
Pays: United States
ID NLM: 7905527

Informations de publication

Date de publication:
Historique:
received: 19 04 2021
revised: 04 06 2021
accepted: 07 06 2021
pubmed: 27 6 2021
medline: 18 3 2022
entrez: 26 6 2021
Statut: ppublish

Résumé

Pain, anxiety, and depression (PAD) are common, co-occurring symptoms that adversely affect one another and may respond to common treatments. PAD composite measures would be useful for tracking treatment response in patients with PAD symptoms. The goal of this study is to compare 3 different PAD composite scales in terms of construct validity, responsiveness, and utility in predicting global improvement. The sample consisted of 294 primary care patients enrolled in a telecare trial for treating pain, anxiety, and depression. Assessments at baseline and 3 months included the Brief Pain Inventory, PHQ-9 depression scale, GAD-7 anxiety scale, PROMIS measures, Medical Outcomes Study Short-Form items, disability measures, and patient-reported global improvement. Construct validity of the PAD composite measures, their responsiveness, and their ability to predict global improvement was analyzed using Pearson correlations, standardized response means, and receiver operating characteristics analysis. PAD composite measures correlated strongly with one another, and moderately with measures of function, vitality, and disability. Each PAD composite measure demonstrated similar responsiveness in detecting improvement at 3 months as assessed by standardized response means (SRMs) and area under the curve (AUC analyses).The SRMs for partial and substantial global improvement corresponded to moderate (Cohen's d of 0.58 to 0.69) and large (0.81 to 0.93) effect sizes, respectively. Three different PAD composite measures demonstrate good construct validity as well as responsiveness in detecting global improvement of pain, anxiety and depression at 3 months.

Identifiants

pubmed: 34174547
pii: S0163-8343(21)00082-7
doi: 10.1016/j.genhosppsych.2021.06.003
pii:
doi:

Types de publication

Clinical Trial Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-6

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Michael A Bushey (MA)

Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, United States. Electronic address: mabushey@iu.edu.

Kurt Kroenke (K)

VA HSR&D Center for Health Information and Communication, Roudebush VA Medical Center, Indianapolis, IN, United States; Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States; Regenstrief Institute, Inc., Indianapolis, IN, United States.

Fitsum Baye (F)

Department of Biostatistics, Indiana University Fairbanks School of Public Health, Indianapolis, IN, United States.

Spencer Lourens (S)

Department of Biostatistics, Indiana University Fairbanks School of Public Health, Indianapolis, IN, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH